Felicia C. Chow

Felicia C. Chow

Auto-generated profile, based on publicly available information

Felicia C. Chow

Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, Box 0896, 2540 23rd Street, Floor 5 (5216), San Francisco, CA, 94110, USA.

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
MWMichael Wilson
Michael Wilson
HSHannah A. Sample
Hannah A. Sample
KZKelsey C. Zorn
Kelsey C. Zorn
SAShaun Arevalo
Shaun Arevalo
GYGuixia Yu
Guixia Yu
CCCharles Y. Chiu
Charles Y. Chiu
Metagenomic next-generation sequencing (NGS) of cerebrospinal fluid (CSF) has the potential to identify a broad range of pathogens in a single test.

1 August 2012 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
FCFelicia C. Chow
Felicia C. Chow
SRSusan Regan
Susan Regan
SFSteven Feske
Steven Feske
JMJames B. Meigs
James B. Meigs
SGSteven K. Grinspoon
Steven K. Grinspoon
VTVirginia A. Triant
Virginia A. Triant
Background: Cardiovascular disease is increased among HIV-infected patients, but little is known regarding ischemic stroke rates. We sought to compare stroke rates and determine stroke risk factors in HIV-infected versus non-HIV-infected patients. Methods: An HIV cohort and matched non-HIV comparator cohort seen between 1996 and 2009 were identified from a Boston health care system. The primary endpoint was ischemic stroke, defined using International Classification of Diseases (ICD) codes. Unadjusted stroke incidence rates were calculated. Cox proportional hazards modeling was used to determine adjusted hazard ratios (HRs). Results: The incidence rate of ischemic stroke was 5.27 per 1000 person-years in HIV-infected compared with 3.75 in non-HIV-infected patients, with an unadjusted HR of 1.40 [95% confidence interval (CI): 1.17 to 1.69, P < 0.001]. HIV remained an independent predictor of stroke after controlling for demographics and stroke risk factors (HR: 1.21, 95% CI: 1.01 to 1.46, P = 0.043). The relative increase in stroke rates (HIV vs. non-HIV) was significantly higher in younger HIV patients (incidence rate ratio: 4.42, 95% CI: 1.56 to 11.09, age 18–29; 2.96, 1.69–4.96, age: 30–39; 1.53, 1.06–2.17, age: 40–49), and in women [HR: 2.16 (95% CI: 1.53 to 3.04) for women vs. HR: 1.18 (95% CI: 0.95 to 1.47) for men]. Among HIV patients, increased HIV RNA (HR: 1.10, 95% CI: 1.04 to 1.17, P = 0.001) was associated with an increased risk of stroke. Conclusions: Stroke rates were increased among HIV-infected patients, independent of common stroke risk factors, particularly among young patients and women.

1 August 2018 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
MWMichael Wilson
Michael Wilson
BOBrian D. O’dOnovan
Brian D. O’dOnovan
JGJeffrey M. Gelfand
Jeffrey M. Gelfand
HSHannah A. Sample
Hannah A. Sample
FCFelicia C. Chow
Felicia C. Chow
JDJoseph L. DeRisi
Joseph L. DeRisi
Subacute and chronic meningitis are diagnostically challenging given the wide range of potential infectious, autoimmune, neoplastic, paraneoplastic, parameningeal, and toxic causes.1,2 Securing a final diagnosis can require weeks or months of testing or remain unsolved, necessitating empirical treatment approaches that may be ineffective or even harmful.

24 August 2014 in AIDS
Verified
Journal Article
Closed access
JMJulia L. Marcus
Julia L. Marcus
WLWendy A. Leyden
Wendy A. Leyden
CCChun R. Chao
Chun R. Chao
FCFelicia C. Chow
Felicia C. Chow
MHMichael A. Horberg
Michael A. Horberg
MSMichael J. Silverberg
Michael J. Silverberg
Objective: To determine the association of HIV infection and immunodeficiency with incidence of ischemic stroke. Design: Cohort study of HIV-positive and matched HIV-negative adult Kaiser Permanente Northern and Southern California (KPNC and KPSC, respectively) members during 1996–2011 (KPNC) or 2000–2011 (KPSC). Methods: We used Poisson models to obtain rate ratios for incident ischemic stroke associated with HIV infection, both overall and stratified by CD4+ cell counts (cells/μl) and HIV RNA copies (copies/ml), with HIV-negative individuals as the reference group. We also obtained rate ratios for risk factors in the HIV-positive subset. Results: Among 24 768 HIV-positive and 257 600 HIV-negative individuals, the ischemic stroke rate per 100 000 person-years was 125 (n = 151 events) for HIV-positive and 74 (n = 1128 events) for HIV-negative individuals, with an adjusted rate ratio of 1.4 [95% confidence interval (CI) 1.2–1.7). Compared with HIV-negative individuals, HIV-positive individuals with recent CD4+ cell counts of 500 cells/μl at least (rate ratio 1.0, 95% CI 0.8–1.4) or recent HIV RNA less than 500 copies/ml (rate ratio 1.1, 95% CI 0.9–1.4) had no excess risk of ischemic stroke, with similar results for HIV-positive individuals with nadir CD4+ cell counts of 500 cells/μl at least (rate ratio 1.4, 95% CI 0.8–2.2) or 200–499 cells/μl (rate ratio 1.2, 95% CI 0.9–1.5). Among HIV-positive individuals only, recent CD4+ cell count less than 200 cells/μl (rate ratio 2.5, 95% CI 1.3–4.6) was associated with an increased risk of ischemic stroke after adjustment for recent HIV RNA and nadir CD4+ cell count, whereas recent HIV RNA and nadir CD4+ were not independent risk factors. Conclusion: Ischemic stroke incidence in HIV-positive individuals with high CD4+ cell count or low HIV RNA is similar to that of HIV-negative individuals.

2 February 2021 in Journal of NeuroVirology
Verified
Journal Article
Open access
PDF file
JHJoanna Hellmuth
Joanna Hellmuth
TBT. Allen Barnett
T. Allen Barnett
BABreton M. Asken
Breton M. Asken
JKJohn Daniel Kelly
John Daniel Kelly
LTLeonel Torres
Leonel Torres
MPMichael J. Peluso
Michael J. Peluso
As cases of coronavirus disease 2019 (COVID-19) mount worldwide, attention is needed on potential long-term neurologic impacts for the majority of patients who experience mild to moderate illness managed as outpatients. To date, there has not been discussion of persistent neurocognitive deficits in patients with milder COVID-19. We present two cases of non-hospitalized patients recovering from COVID-19 with persistent neurocognitive symptoms. Commonly used cognitive screens were normal, while more detailed testing revealed working memory and executive functioning deficits. An observational cohort study of individuals recovering from COVID-19 (14 or more days following symptom onset) identified that among the first 100 individuals enrolled, 14 were non-hospitalized patients reporting persistent cognitive issues. These 14 participants had a median age of 39 years (interquartile range: 35–56), and cognitive symptoms were present for at least a median of 98 days (interquartile range: 71–120 following acute COVID-19 symptoms); no participants with follow-up evaluation reported symptom resolution. We discuss potential mechanisms to be explored in future studies, including direct viral effects, indirect consequences of immune activation, and immune dysregulation causing auto-antibody production.

30 January 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FCFelicia C. Chow
Felicia C. Chow
CGCarol A. Glaser
Carol A. Glaser
HSHeather Sheriff
Heather Sheriff
DXDongxiang Xia
Dongxiang Xia
SMSharon Messenger
Sharon Messenger
AVArun Venkatesan
Arun Venkatesan
Background. We describe the spectrum of etiologies associated with temporal lobe (TL) encephalitis and identify clinical and radiologic features that distinguish herpes simplex encephalitis (HSE) from its mimics. Methods. We reviewed all adult cases of encephalitis with TL abnormalities on magnetic resonance imaging (MRI) from the California Encephalitis Project. We evaluated the association between specific clinical and MRI characteristics and HSE compared with other causes of TL encephalitis and used multivariate logistic modeling to identify radiologic predictors of HSE. Results. Of 251 cases of TL encephalitis, 43% had an infectious etiology compared with 16% with a noninfectious etiology. Of infectious etiologies, herpes simplex virus was the most commonly identified agent (n = 60), followed by tuberculosis (n = 8) and varicella zoster virus (n = 7). Of noninfectious etiologies, more than half (n = 21) were due to autoimmune disease. Patients with HSE were older (56.8 vs 50.2 years; P = .012), more likely to be white (53% vs 35%; P = .013), more likely to present acutely (88% vs 64%; P = .001) and with a fever (80% vs 49%; P < .001), and less likely to present with a rash (2% vs 15%; P = .010). In a multivariate model, bilateral TL involvement (odds ratio [OR], 0.38; 95% confidence interval [CI], .18–.79; P = .010) and lesions outside the TL, insula, or cingulate (OR, 0.37; 95% CI, .18–.74; P = .005) were associated with lower odds of HSE. Conclusions. In addition to HSE, other infectious and noninfectious etiologies should be considered in the differential diagnosis for TL encephalitis, depending on the presentation. Specific clinical and imaging features may aid in distinguishing HSE from non-HSE causes of TL encephalitis.